REal-World Treatment Outcomes of Oral-Anticoagulants Among Patients With Atrial Fibrillation - Patient Survey - RETAF-PS
Latest Information Update: 19 Dec 2023
At a glance
- Drugs Apixaban (Primary)
- Indications Stroke; Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms RETAF-PS
- Sponsors Bayer
- 11 Dec 2023 Status changed from active, no longer recruiting to completed.
- 25 Oct 2023 Planned End Date changed from 30 Nov 2023 to 31 Dec 2023.
- 25 Oct 2023 Planned primary completion date changed from 30 Nov 2023 to 31 Dec 2023.